Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy

Vaccine

Volumn 31, Issue 4, 2013, Pages 639-646

  Hansen, Morten ^a   Hjortø, Gertrud Malene ^b   Donia, Marco ^a,c   Met, özcan ^a   Larsen, Niels Bent ^b   Andersen, Mads Hald ^a   thor Straten, Per ^a   Svane, Inge Marie ^a  

^a Mental Health Services CPH   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Dendritic cells; Immunotherapy; Maturation cocktails; Transwell migration; Type 1 polarization

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MELAN A; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL;

CANCER VACCINES; CELL DIFFERENTIATION; CELL LINE; CELL MOVEMENT; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; LIPID A; NEOPLASMS; TH1 CELLS;

EID: 84871937876     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.053     Document Type: Article

References (43)

1. Hansen M., Met O., Svane I.M., Andersen M.H. Cellular based cancer vaccines: type 1 polarization of dendritic cells. Curr Med Chem 2012, 19:4239-4246.
2. Jonuleit H., Kühn U., Müller G., Steinbrink K., Paragnik L., Schmitt E., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum free conditions. Eur J Immunol 1997, 27(12):3135-3142.
3. Draube A., Klein-González N., Mattheus S., Brillant C., Hellmich M., Engert A., et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PloS One 2011, 6(4):e18801.
4. Engell-Noerregaard L., Hansen T.H., Andersen M.H., thor Straten P., Svane I.M. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009, 58(1):1-14.
5. Schadendorf D., Ugurel S., Schuler-Thurner B., Nestle F., Enk A., Bröcker E.B., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006, 17(4):563-570.
6. Verdijk P., Aarntzen E.H.J.G., Lesterhuis W.J., Boullart A.C.I., Kok E., van Rossum M.M., et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009, 15(7):2531-2540.
7. Muthuswamy R., Urban J., Lee J.J., Reinhart T.A., Bartlett D., Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 2008, 68(14):5972-5978.
8. Rosenberg S.A., Sherry R.M., Morton K.E., Scharfman W.J., Yang J.C., Topalian S.L., et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8 T cells in patients with melanoma. J Immunol 2005, 175(9):6169-6176.
9. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.
10. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331(6024):1565-1570.
11. O'Garra A., Murphy K.M. From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce TH1 development. Nat Immunol 2009, 10(9):929-932.
12. Bogunovic D., Manches O., Godefroy E., Yewdall A., Gallois A., Salazar A.M., et al. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 2011, 71(16):5467-5476.
13. Macagno A., Napolitani G., Lanzavecchia A., Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends Immunol 2007, 28(5):227-233.
14. Mailliard R.B., Wankowicz-Kalinska A., Cai Q., Wesa A., Hilkens C.M., Kapsenberg M.L., et al. α-type-1 polarized dendritic cells. Cancer Res 2004, 64(17):5934-5937.
15. Xu S., Koski G.K., Faries M., Bedrosian I., Mick R., Maeurer M., et al. Rapid high efficiency sensitization of CD8 T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003, 171(5):2251-2261.
16. Felzmann T., Hüttner K.G., Breuer S.K., Wimmer D., Ressmann G., Wagner D., et al. Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol Immunother 2005, 54(8):769-780.
17. Ten Brinke A., Karsten M.L., Dieker M.C., Zwaginga J.J., Van Ham S.M. The clinical grade maturation cocktail monophosphoryl lipid A plus IFN [gamma] generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine 2007, 25(41):7145-7152.
18. Spranger S., Javorovic M., Bürdek M., Wilde S., Mosetter B., Tippmer S., et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 2010, 185(1):738-747.
19. Koski G.K., Lyakh L.A., Rice N.R. Rapid lipopolysaccharide-induced differentiation of CD14 monocytes into CD83 dendritic cells is modulated under serum-free conditions by exogenously added IFN-γ and endogenously produced IL-10. Eur J Immunol 2001, 31(12):3773-3781.
20. Vieira P.L., de Jong E.C., Wierenga E.A., Kapsenberg M.L., Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000, 164(9):4507-4512.
21. Paustian C., Caspell R., Johnson T., Cohen P.A., Shu S., Xu S., et al. Effect of multiple activation stimuli on the generation of Th1-polarizing dendritic cells. Hum Immunol 2011, 72(1):24-31.
22. Schreibelt G., Benitez-Ribas D., Schuurhuis D., Lambeck A.J.A., van Hout-Kuijer M., Schaft N., et al. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 2010, 116(4):564-574.
23. Jongmans W., Tiemessen D.M., van Vlodrop I.J.H., Mulders P.F.A., Oosterwijk E. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother 2005, 28(5):480-487.
24. Hovden A.O., Karlsen M., Jonsson R., Aarstad H.J., Appel S. Maturation of monocyte derived dendritic cells with OK432 boosts IL-12p70 secretion and conveys strong T-cell responses. J Transl Med 2011, 12(1):2-12.
25. Scandella E., Men Y., Gillessen S., Förster R., Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002, 100(4):1354-1361.
26. Luft T., Jefford M., Luetjens P., Toy T., Hochrein H., Masterman K.A., et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets. Blood 2002, 100(4):1362-1372.
27. Krause P., Bruckner M., Uermösi C., Singer E., Groettrup M., Legler D.F. Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood 2009, 113(11):2451-2460.
28. Van der Pouw Kraan T.C., Boeije L., Smeenk R., Wijdenes J., Aarden L.A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med 1995, 181(2):775-779.
29. Kalinski P., Vieira P.L., Schuitemaker J.H.N., de Jong E.C., Kapsenberg M.L. Prostaglandin E2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001, 97(11):3466-3469.
30. Minkis K., Kavanagh D.G., Alter G., Bogunovic D., O'Neill D., Adams S., et al. Type 2 bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res 2008, 68(22):9441-9450.
31. von Bergwelt-Baildon M.S., Popov A., Saric T., Chemnitz J., Classen S., Stoffel M.S., et al. CD25 and indoleamine 2, 3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006, 108(1):228-237.
32. Dauer M., Lam V., Arnold H., Junkmann J., Kiefl R., Bauer C., et al. Combined use of toll-like receptor agonists and prostaglandin E2 in the FastDC model: Rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. J Immunol Methods 2008, 337(2):97-105.
33. Jonuleit H., Kühn U., Müller G., Steinbrink K., Paragnik L., Schmitt E., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997, 27(12):3135-3142.
34. Butterfield L.H., Gooding W., Whiteside T.L. Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother 2008, 31(1):89.
35. Hadrup S.R., Bakker A.H., Shu C.J., Andersen R.S., van Veluw J., Hombrink P., et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009, 6(7):520-526.
36. Donia M., Junker N., Ellebaek E., Andersen M.H., Straten P., Svane I.M. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Scand J Immunol 2012, 75(2):157-167.
37. Muthuswamy R., Mueller-Berghaus J., Haberkorn U., Reinhart T.A., Schadendorf D., Kalinski P. PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 2010, 116(9):1454-1459.
38. Otero C., Groettrup M., Legler D.F. Opposite fate of endocytosed CCR7 and its ligands: recycling versus degradation. J Immunol 2006, 177(4):2314-2323.
39. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007, 117(5):1195-1203.
40. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8(8):793-800.
41. Frigola X., Inman B.A., Lohse C.M., Krco C.J., Cheville J.C., Thompson R.H., et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res 2011, 17(7):1915.
42. Dannull J., Schneider T., Lee W.T., de Rosa N., Tyler D.S., Pruitt S.K. Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function. Blood 2012, 119(13):3113-3122.
43. Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T.E., et al. Induction of CD8 T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011, 29(3):330-336.